WuXi AppTec's Global Footprint: Serving Partners Across Asia, Europe, and North America
Where Is WuXi AppTec Located? A Global Presence Across Three Continents
WuXi AppTec today operates across Asia, Europe and North America, with sites in China, Germany, Japan, Singapore, South Korea, Switzerland, and the United States. This global footprint is part of a CRDMO platform designed to integrate key stages of drug development.
Integration of Local Strengths
In Europe, the Munich site in Germany focuses on early-stage discovery, including biophysical analysis, crystallography, and protein science. The Couvet site in Switzerland plays a complementary role in late-stage clinical and commercial production, offering flexibility in manufacturing and packaging. In North America, operations in San Diego and New Jersey support programs in biology, pharmacology, and testing. Together, these facilities demonstrate how regional expertise is interconnected through the CRDMO framework, enabling projects to progress through various stages of development within a single network.
WuXi AppTec’s Expanding Footprint in Asia
Alongside its established sites, WuXi AppTec is expanding further in Asia. A notable example is the Singapore site, in May 2024, WuXi AppTec broke ground to build the R&D and manufacturing site in Singapore, with its Phase I portion expected to commence operations in 2027. The new 50-acre Singapore site is located in the thriving Tuas Biomedical Park to encompass a total of seven plants at its full capacity, providing CRDMO services across small molecules, oligonucleotides, peptides, and complex synthetic conjugates. As a key part of the company’s global network, the Singapore site will integrate closely with WuXi AppTec’s existing sites across Asia, Europe, and North America, offering effective CRDMO solutions for new drug R&D from discovery to commercialization with expanded flexibility and scalability.
The Practical Impact of a Global Footprint
Operating across three continents allows WuXi AppTec to support its CRDMO model, where research, development, and manufacturing are treated as connected stages rather than separate activities. This integrated CRDMO approach creates momentum by reducing transfer risks, shortening timelines, and lowering barriers for innovators. A global presence also makes it easier to coordinate with regulators, and share expertise across scientific ecosystems. Biotech start-ups and established pharmaceutical companies can both benefit from this structure, as it provides continuity from early discovery through commercial production. By embedding the CRDMO model into its operations, WuXi AppTec demonstrates how global networks can accelerate the delivery of new therapies.
Enabling Global Healthcare Progress
WuXi AppTec’s CRDMO model, supported by its worldwide network, integrates research, development, and manufacturing within a single platform. This approach allows customers to initiate projects in one region and continue them in another without rebuilding infrastructure or switching providers, reducing transfer risks and shortening development timelines. By embedding the model into a global network, WuXi AppTec enables innovators to scale their work more efficiently and maintain continuity from early discovery through commercial production. With a customer base of thousands of partners worldwide, this combination of global reach and integrated capabilities illustrates how a global platform can support innovation while keeping development closely aligned with patient needs.
WuXi AppTec
WuXi AppTec
+86 21 2066 3734
wuxiconcierge@wuxiapptec.com
Visit us on social media:
LinkedIn
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
